Endogenous Nitric Oxide Synthesis Inhibitor Asymmetric Dimethyl l -Arginine Accelerates Endothelial Cell Senescence
- 1 October 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (10) , 1816-1822
- https://doi.org/10.1161/01.atv.0000141843.77133.fc
Abstract
Objectives— Asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS), and its accumulation has been associated with cardiovascular disease. We aimed to investigate the role of ADMA in endothelial cell senescence. Methods and Results— Endothelial cells were cultured until the tenth passage. ADMA was replaced every 48 hours starting at the fourth passage. ADMA significantly accelerated senescence associated β-galactosidase activity. Additionally, the shortening of telomere length was significantly accelerated and the telomerase activity was significantly reduced. This effect was associated with an increase of oxidative stress: allantoin, a marker of oxygen free radical generation, and intracellular reactive oxygen species (ROS) increased significantly after ADMA treatment compared with control, whereas cellular thiol status and NOx synthesis decreased. Furthermore, ADMA-increased oxidative stress was accompanied by a decrease in the activity of dimethylarginine dimethylaminohydrolase (DDAH), the enzyme that degrades ADMA, which could be prevented by the antioxidant pyrrolidine dithiocarbamate. Exogenous ADMA also stimulated secretion of MCP-1 and interleukin-8. Coincubation with the methyltransferase inhibitor S-adenosylhomocysteine abolished the effects of ADMA. Conclusions— These data suggest that ADMA accelerates senescence, probably via increased oxygen radical formation by inhibiting nitric oxide elaboration. This study provides evidence that modest changes of intracellular ADMA levels are associated with significant effects on slowing endothelial senescence. We aimed to investigate the role of asymmetrical dimethylarginine (ADMA), a novel cardiovascular risk factor, in endothelial cell senescence. We found that at concentrations corresponding to plasma levels at pathophysiological conditions, ADMA accelerates aging in endothelial cells, probably via increased oxygen radical formation by inhibiting nitric oxide elaboration via decreased dimethylarginine dimethylaminohydrolase activity.Keywords
This publication has 22 references indexed in Scilit:
- Antioxidants Inhibit Nuclear Export of Telomerase Reverse Transcriptase and Delay Replicative Senescence of Endothelial CellsCirculation Research, 2004
- Homocysteine Mediated Expression and Secretion of Monocyte Chemoattractant Protein-1 and Interleukin-8 in Human MonocytesCirculation Research, 2003
- Asymmetric Dimethylarginine, Blood Pressure, and Renal Perfusion in Elderly SubjectsCirculation, 2003
- ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of ?-arginine and B vitaminsCardiovascular Research, 2003
- Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathyFree Radical Biology & Medicine, 2002
- Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart FailureCirculation, 2002
- Endothelial Cell Senescence in Human AtherosclerosisCirculation, 2002
- Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolaseBritish Journal of Pharmacology, 1996
- Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography—mass spectrometry using their 15N-labelled analogsJournal of Chromatography B: Biomedical Sciences and Applications, 1994
- Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in womenJournal of the American College of Cardiology, 1994